BioAge Labs, Inc.
Case Overview
Status: | Status: Investigating |
Company Name: | Company Name: BioAge Labs, Inc. |
Ticker: | Ticker: BIOA |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ:BIOA). The investigation concerns whether BioAge and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
On December 6, 2024, BioAge announced that it discontinued its STRIDES Phase 2 trial for its lead product candidate, azelaprag, citing safety concerns, after liver transaminitis was observed in subjects receiving azelaprag. BioAge stated that the decision to discontinue the STRIDES Phase 2 study of azelaprag “became clear” due to “the emerging safety profile of the current doses tested.” On this news, the price of BioAge stock fell by $15.44 per share, or approximately 76%, from $20.09 per share on December 6, 2024, to close at $4.65 on December 9, 2024.
On December 6, 2024, BioAge announced that it discontinued its STRIDES Phase 2 trial for its lead product candidate, azelaprag, citing safety concerns, after liver transaminitis was observed in subjects receiving azelaprag. BioAge stated that the decision to discontinue the STRIDES Phase 2 study of azelaprag “became clear” due to “the emerging safety profile of the current doses tested.” On this news, the price of BioAge stock fell by $15.44 per share, or approximately 76%, from $20.09 per share on December 6, 2024, to close at $4.65 on December 9, 2024.